The Hims & Hers Masterstroke: How One Telehealth Platform Outmaneuvered a European Pharma Giant

Neither a grandiose keynote address nor a boardroom announcement brought about the change. In the midst of a disagreement, it happened more subtly, almost awkwardly. Attorneys are circling. The tone of press releases is becoming tighter. Suddenly, there was a reversal. As you watch it unfold, you get the impression that Hims & Hers changed the plot in the middle of a confrontation with a major European pharmaceutical company.

Offering compounded versions of semaglutide, the molecule behind popular medications like Wegovy, the telehealth company had been operating for months in what many in the industry referred to as a gray area. Regulators felt uncomfortable. Executives in the pharmaceutical industry were clearly annoyed. The Danish behemoth that created the original medication, Novo Nordisk, retaliated in court, claiming that these imitations blurred the distinction between innovation and imitation.

It appeared to be a traditional David-versus-Goliath tale at first, but David was expanding quickly, generating almost $1.5 billion in revenue and expanding at a rate that conventional pharmaceutical companies hardly ever match. Doctors used screens to write prescriptions in remote clinics and small offices, and fulfillment centers delivered medications right to patients’ doorsteps. No waiting areas. No insurance documents. Just quickness. It turns out that speed can also be confusing.

The pivot then appeared. Rather than carry on the battle, Hims & Hers reached an agreement with Novo Nordisk to cease marketing compounded GLP-1 medications and instead use its platform to distribute the official, branded versions. Almost overnight, the lawsuit vanished. Hims & Hers shares surged by over 40% as a result of the partnership that replaced it.

It’s difficult to ignore the timing. When pressure increased, the company didn’t back down; instead, it seized the opportunity to turn legal friction into distribution leverage. It appeared to be interpreted by investors as a sign of maturity—or possibly opportunism. However, there is more to the deeper story than just one transaction. It has to do with control.

Pharmacy benefit managers negotiate prices, wholesalers handle logistics, and insurers shape access in the well-known layered traditional pharmaceutical supply chains. Patients frequently feel like afterthoughts because they are caught in the middle. By creating a vertically integrated system where diagnosis, prescription, and delivery take place within the same digital ecosystem, Hims & Hers has been eroding that structure.

It has a certain grace to it. Days later, a patient receives medication after logging in, completing a questionnaire, and speaking with a clinician. There are no visible middlemen. Another question is whether that simplicity can be sustained.

Hims & Hers entered a new regulatory environment in addition to expanding geographically by purchasing Zava, a European telemedicine provider with more than a million users. The concept of a private platform providing quick, paid access is appealing and unsettling in countries like the UK, where the NHS still controls access to costly treatments like semaglutide.

It’s easy to see why telehealth seems appealing when you pass a typical GP clinic in London, where patients are waiting in line outside and appointments are delayed. However, there is tension as well. Faster access is frequently more expensive. Furthermore, not everyone has the means to bypass the line.

For its part, Novo Nordisk seems to have made a sensible decision. It effectively turned a disruptor into a sales channel by partnering with one of the biggest platforms instead of competing with a dispersed network of telehealth providers offering compounded alternatives. This could be an indication of a more general change in pharmaceutical strategy—less resistance, more adaptation. Even so, there seems to be an imbalance of power.

Hims & Hers is currently in a unique position, serving as a distribution layer for well-known pharmaceutical brands as well as a healthcare provider. It is in charge of the data, the patient interface, and increasingly the narrative surrounding care. The front door, where patients initially enter the system, is changing, but pharmaceutical companies continue to control the drugs. There is a small but significant distinction there.

The company doesn’t seem to be satisfied with being merely a middleman, as evidenced by its earlier move into vertical integration and acquisition of manufacturing and lab-testing capabilities. Owning a portion of the supply chain allows for flexibility, particularly in times of shortages, but it also raises concerns about long-term margins and regulatory boundaries.

In the meantime, rivals like Ro are adopting a more cooperative approach, integrating themselves further into the established ecosystem as opposed to attempting to get around it. Two approaches, silently diverging. While one works within the system, the other pushes against it. It’s still unclear which is more resilient over time.

One thing is certain: telehealth is no longer a side project. It’s evolving into infrastructure. The kind that changes people’s perceptions of what healthcare should be like on a typical Tuesday afternoon, how quickly care should be provided, and how much friction people are willing to put up with. Maybe that’s the true masterwork.

Not only can a legal threat be transformed into a partnership, but patients‘ expectations of the system itself can be gradually altered. It is difficult to go back once that expectation has changed.